Study on Carboplatin, Paclitaxel, and Ramucirumab for Non-Small Cell Lung Cancer After Pemetrexed or Pembrolizumab Maintenance

Sponsor: Abramson Cancer Center at Penn Medicine

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT04332367

Provider View

This clinical trial is testing whether a combination of three drugs—carboplatin, paclitaxel, and ramucirumab—can help shrink tumors or slow down their growth in patients with non-small cell lung cancer (NSCLC). The study also aims to determine if this drug combination is safe for patients.

Patient Parameters

Program Overview

The goal of this study is to find out if using a combination of three anti-cancer drugs—carboplatin, paclitaxel, and ramucirumab—can effectively reduce the size of tumors or delay their growth in patients with non-small cell lung cancer (NSCLC). Additionally, the study will evaluate the safety of using these drugs together.

Eligibility Criteria

Inclusion Criteria

  • Have advanced non-squamous non-small cell lung cancer (NSCLC) that is either Stage IV or has come back after initial treatment aimed at curing it.
  • Be 18 years or older.
  • Have previously received 4 to 6 cycles of treatment with Pemetrexed, Carboplatin, and Pembrolizumab, and experienced disease progression after at least 18 weeks of maintenance therapy with Pemetrexed, Pembrolizumab, or both.
  • Have a performance status score of 0 or 1, indicating full activity or some restriction in strenuous activities.

Exclusion Criteria

  • Have a specific genetic mutation that can be treated with targeted therapy.
  • Have another active invasive cancer that requires ongoing treatment.
  • Have moderate to severe nerve damage causing numbness or tingling.
  • Have untreated cancer that has spread to the brain.
  • Have a history of bleeding disorders or recent significant coughing up of blood (more than 1/2 teaspoon in the past 2 months).

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.